on The Vanguard Group, Inc. (isin : US12572Q1058)
Vanguard Group Discloses Stake in Avadel Pharmaceuticals
The Vanguard Group, Inc. has released its Form 8.3, detailing its stake in Avadel Pharmaceuticals plc as required by the Irish Takeover Panel Act, 1997. Vanguard owns 5,523,543 US$0.01 ordinary shares, representing a 5.67% interest in Avadel Pharmaceuticals. This positions Vanguard as a significant shareholder with interests surpassing the 1% disclosure threshold.
The disclosure, dated November 10, 2025, confirms that Vanguard has been involved in recent purchase activity. A transaction included the purchase of 133 ordinary shares at a price of 18.70 USD each. No cash-settled or stock-settled derivative transactions were reported.
No indemnity, option arrangements or formal agreements affecting Avadel's relevant securities have been reported by Vanguard. The submission of this document ensures compliance with Irish takeover rules, promoting transparency regarding significant shareholdings.
R. P.
Copyright © 2025 FinanzWire, all reproduction and representation rights reserved.
Disclaimer: although drawn from the best sources, the information and analyzes disseminated by FinanzWire are provided for informational purposes only and in no way constitute an incentive to take a position on the financial markets.
Click here to consult the press release on which this article is based
See all The Vanguard Group, Inc. news